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series of 16 patients from southern Japan. The acute (60%) and
lymphomatous (20%) types, which account for the majority of
cases, are aggressive lymphomas characterized by rapid progression. In the absence of therapy, survival is measured in days.
ATL patients are acutely ill with rapidly rising peripheral blood
cell counts and leukemic infiltration of the liver, spleen, lungs,
bone marrow, central nervous system, and gastrointestinal
tract (1–6). ATL is also associated with severe hypercalcemia,
which results from the expression of parathyroid hormone-related protein (PTHrP) and receptor activator of NF-B ligand
(RANKL) by leukemic cells (7, 8).
Treatment consists of combinations of cytotoxic chemotherapy, which include an alkylating agent (cyclophosphamide),
microtubule poison (vincristine), anthracycline (hydroxydaunorubicin), and topoisomerase II inhibitor (etoposide);
more aggressive regimens improve response rates at the cost of
increased toxicity (9, 10). Lenalidomide, a thalidomide analog
approved to treat multiple myeloma, has been shown to have
activity in relapsed and refractory ATL. However, 70% of
patients develop progressive disease within 5 months of treatment with this agent (11). The introduction in Japan of the
novel anti-CCR4 – directed mAb, mogamulizumab, improved
response rates at the cost of increased risk of graft versus host
disease in patients who subsequently receive an allogeneic stem
cell transplant (12, 13). Allogeneic stem cell transplant remains
the only known curative therapy, but it is associated with considerable short-term morbidity and mortality (14). Despite
aggressive treatment, the majority of patients relapse, and the
4-year survival is ⬍10%, with a median survival of 10 months.
Human T-cell leukemia virus type 1 (HTLV-1), the first retrovirus known to infect humans, was discovered by Gallo and
colleagues in 1981 and is the etiological agent of ATL (15). ATL
cells carry clonally integrated copies of the HTLV-1 genome,
(Fas-associated death domain-like interleukin 1␤-converting enzyme-like
inhibitory protein); HTLV, human T-cell leukemia virus; IL, interleukin; IRF,
interferon regulatory factor; NF-B, nuclear factor of the  light chain
enhancer of activated B cells; OKT3, Muromonab-CD3; PBMC, peripheral
blood mononuclear cell; RPMI medium, Roswell Park Memorial Institute
medium; Tax, HTLV viral transactivator; TCR, T-cell receptor; SNV, singlenucleotide variation; ISRE, interferon-stimulated response element; EICE,
ETS-IRF composite element; AICE, AP1-IRF4 composite element; qPCR and
qRT-PCR, quantitative PCR and RT-PCR, respectively; HGPRT, hypoxanthine
guanine phosphoribosyl transferase; ABC, activated B-cell; DLBCL, diffuse
large B-cell lymphoma; MSCV, murine stem cell virus; IRES, internal ribosome entry site; GFP, green fluorescent protein; TK, thymidine kinase.
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The human T-cell leukemia virus-1 (HTLV-1) oncoprotein
Tax drives cell proliferation and resistance to apoptosis early in
the pathogenesis of adult T-cell leukemia (ATL). Subsequently,
probably as a result of specific immunoediting, Tax expression is
down-regulated and functionally replaced by somatic driver
mutations of the host genome. Both amplification and point
mutations of interferon regulatory factor 4 (IRF4) have been
previously detected in ATL., K59R is the most common singlenucleotide variation of IRF4 and is found exclusively in ATL.
High-throughput whole-exome sequencing revealed recurrent
activating genetic alterations in the T-cell receptor, CD28, and
NF-B pathways. We found that IRF4, which is transcriptionally
activated downstream of these pathways, is frequently mutated
in ATL. IRF4 RNA, protein, and IRF4 transcriptional targets are
uniformly elevated in HTLV-1–transformed cells and ATL cell
lines, and IRF4 was bound to genomic regulatory DNA of many
of these transcriptional targets in HTLV-1–transformed cell
lines. We further noted that the K59R IRF4 mutant is expressed
at higher levels in the nucleus than WT IRF4 and is transcriptionally more active. Expression of both WT and the K59R
mutant of IRF4 from a constitutive promoter in retrovirally
transduced murine bone marrow cells increased the abundance
of T lymphocytes but not myeloid cells or B lymphocytes in
mice. IRF4 may represent a therapeutic target in ATL because
ATL cells select for a mutant of IRF4 with higher nuclear expression and transcriptional activity, and overexpression of IRF4
induces the expansion of T lymphocytes in vivo.

IRF4 activation in ATL
IRF-binding element or interferon-stimulated response element (ISRE) (38).
In B cells, IRF4-PU.1 or IRF4-Spi-B heterodimers bind to
ETS-IRF composite elements (EICEs) to activate transcription
of B cell–specific IRF4 targets (35, 39). In T cells, IRF4 complexes with BATF and JunD to bind to AP1-IRF4 composite
elements (AICEs) and activate an IRF4 transcriptional program
unique to T cells (40). At the intersection of IRF4 transcriptional targets and ATL– up-regulated genes lies a set of genes
that are potential transcriptional targets of IRF4 in ATL and
may be critical for maintaining the transformed phenotype
downstream of IRF4; these genes may represent additional targets for therapy of IRF4-driven malignancies.

Results
IRF4 is recurrently mutated in ATL
Previous studies suggested that IRF4 is recurrently mutated
at K59R in ATL (Fig. 1, A and B) (22). We interrogated the
COSMIC database to identify mutations of IRF4 previously
detected in lymphoid malignancies. Of all single-nucleotide
variations (SNVs) of IRF4 in the COSMIC database, K59R is the
most common point mutation of IRF4 in lymphoid malignancies and is exclusive to ATL. We noted that other mutations of
IRF4 also concentrate in the DNA-binding domain of IRF4 (Fig.
1B). We performed whole-exome sequencing on peripheral
blood mononuclear cells (PBMCs) of nine patients with acute
ATL. Five of nine patients (56%) had detectable somatic mutations of IRF4. Three of nine (33%) carried a K59R mutation, one
patient had an L70V mutation, and one patient carried an
S149N mutation. One patient, who initially presented with
unfavorable chronic ATL with a white blood cell count of
⬎50,000/l, did not carry a K59R mutation at presentation (0 of
188 reads). This patient achieved a complete remission following treatment with interferon ␣ and zidovudine but, 5 years
later, relapsed with lymphoma subtype of ATL with bulky
lymphadenopathy. Repeat sequencing at that time revealed the
IRF4 K59R mutation in 30 of 156 reads, suggesting that the
emergence of this mutation correlated with progression of
disease.
Lysine 59 of IRF4 lies within the DNA-binding domain of
IRF4 (Fig. 1B), which has a helix-loop-helix tertiary structure
with five conserved tryptophans, which are characteristic of the
DNA-binding domains of interferon regulatory factors (41).
Comparison of the amino acid sequence adjacent to the
mutated lysine in IRF4 reveals that this region is highly conserved across evolutionarily diverse species (Fig. 1C), suggesting that this is a functionally important region of the protein.
Moreover, the Lys-59 position in IRF4 corresponds to either a
lysine or arginine in all other IRFs (Fig. 1D), suggesting that the
K59R mutation is unlikely to result in loss of function.
IRF4 lies downstream of mutations in the TCR, CD28, and
NF-B signaling pathways, suggesting that it is a rational target
for further study and for the design of future ATL therapies.
Kataoka et al. (22) demonstrated that these pathways are frequently activated in ATL, as a result of gene amplification or
gain-of-function mutations in Vav1, phospholipase C␥1, proJ. Biol. Chem. (2018) 293(18) 6844 –6858
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most commonly introduced through vertical transmission in
infancy, followed by decades of asymptomatic latency. Expression of Tax, a potent oncogene and viral trans-activator, from
the positive strand of the integrated HTLV-1 genome is necessary for leukemia initiation. Tax-induced activation of the
NF-B pathway plays a critical role in leukemia initiation (16).
Activation of other pathways, such as the PI3K-Akt-mTOR by
Tax, may also play a role in transformation (17). In addition,
HTLV-1 up-regulates its own transcription via Tax-induced
activation of the viral 5⬘-long terminal repeat. Progression to
aggressive forms of ATL is marked by decreased Tax expression, decreased transcription from the positive strand of the
virus, and proviral DNA methylation or mutation, as a result of
Tax-specific immunoediting (18 –21). At this stage, proliferation is sustained by cellular genes, mutated or epigenetically
altered by events during leukemia initiation and progression.
The identification and characterization of these cellular oncogenes and confirmation of their role as drivers of ATL will be
critical for the design of new therapies.
The alterations that sustain the leukemic state recapitulate
the effects of Tax, including activation of the NF-B pathway
(22). Targeting NF-B is, therefore, a logical approach. However, a trial of bortezomib in ATL failed to demonstrate benefit
over standard therapy (10). High-throughput whole-genome,
exome, and RNA-Seq data revealed consistent overexpression
and recurrent genetic alterations of the cellular proto-oncogene interferon regulatory factor 4 (IRF4/MUM1) in ATL (22).
IRF4 expression is also associated with resistance to antiviral
therapy (23, 24). Moreover, IRF4 is expressed in ATL but not in
other nonneoplastic HTLV-1–associated pathologies, such as
tropical spastic paraparesis, suggesting that its role is unique to
the process of malignant transformation initiated by the virus
(25).
IRF4 is an established oncogene in other lymphoid malignancies, such as activated B-cell diffuse large B-cell lymphoma
(ABC-DLBCL), subtypes of pediatric germinal center DLBCL
(GC-DLBCL) and follicular lymphoma, Hodgkin lymphoma,
and multiple myeloma. IRF4 represses key genes involved in the
mitotic checkpoint, DNA repair, and apoptotic pathways (26 –
31). In addition, IRF4 transforms fibroblasts in culture and is
essential for Epstein-Barr virus–induced transformation of B
cells in vitro, a phenomenon with many parallels to HTLV-1–
induced T-cell transformation (32). Therefore, IRF4 may be
relevant to the design of novel therapeutic strategies for these
therapy-resistant malignancies.
IRF1 to -9 constitute a family of transcription factors that
play key roles in innate and acquired immunity. IRF4, a lymphoid-specific IRF, was initially identified as a transcription factor that binds the 3⬘-enhancer of the  immunoglobulin light
chain gene as a heterodimer with the E-twenty-six (ETS) transcription factor PU.1 (Spi-1) (33, 34). IRF4 has two key
domains, an N-terminal DNA-binding domain and a C-terminal regulatory domain, which contains an IRF autoinhibitory
domain that hydrophobically interacts with and masks the
DNA-binding domain (35). Although IRF4, by itself, weakly
binds DNA, binding to specific heterodimerization partners
relieves autoinhibition, leading to high-affinity DNA binding
(36, 37). IRF4 binds as a homodimer to direct repeats of the

IRF4 activation in ATL

tein kinases C␤ and C, caspase-recruitment domain 11, tumor
necrosis factor receptor–associated factor 3, and CD28 (Fig. 2).
IRF4 is highly expressed in HTLV-1–transformed and ATL cell
lines
To determine the level of expression of IRF4 protein in
HTLV-1–transformed and ATL cell lines (Fig. 3A), we performed Western blotting of whole-cell lysates of activated
PBMCs (lane 1); HTLV-1–negative Jurkat cells (lane 2); HTLV1–positive, Tax-positive cell lines MT2 (lane 3) and MT4 (lane
4); and HTLV-1–positive, Tax-negative cell lines TL-OM1
(lane 5), MT1 (lane 6), and ED40515 (lane 7). Densitometry was
normalized to the levels observed in CD3/CD28-activated
PBMCs. Ratios of IRF4 to actin measured by densitometry, normalized to that of CD3/CD28-activated PBMCs, demonstrated
extremely low levels of IRF4 expression in Jurkat cells. The ratio
of IRF4 to actin was higher in MT2 cells (1.36-fold), MT4
cells (2.89-fold), TL-OM1 (1.98-fold), MT1 (3.88-fold), and
ED40515 (1.53-fold) than in activated PBMCs. Compared with
Jurkat cells, MT2 cells showed 177-fold, MT4 cells 376-fold,
TL-OM1 cells 258-fold, MT1 cells 504-fold, and ED40515 cells
198-fold elevation of IRF4 protein expression as determined by
semiquantitative densitometry. A Tax blot demonstrates a specific band between 50 and 75 kDa corresponding to the Envelope-Tax fusion protein, which is expressed in MT2 cells (lane
3, middle blot, top arrow). Bands corresponding to Tax were
seen at 40 kDa in MT2 cells and MT4 cells (bottom arrow). Tax
expression was not seen in PBMCs or Jurkat cells and was undetectable in the Tax-negative ATL cell lines TL-OM1, MT1, and
ED40515.
IRF4 is bound to genomic regulatory DNA of transcriptional
targets
To determine whether IRF4 is bound to its transcriptional
targets in HTLV-1–transformed and ATL cell lines, we performed ChIP assays on CD3/CD28-activated PBMCs and Jur-
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Figure 2. IRF4 lies downstream of constitutively activated T-cell receptor
and CD28 pathways in ATL cells. Shown are the percentage of cases in
which each of the proteins upstream of IRF4 in the T-cell receptor, CD28, and
NF-B pathways is mutated in Kataoka et al. (22). SNVs are depicted in black
type and copy number variations (CNV) in white type. Note that in ATL, protein
kinase C␤ is exclusively altered by point mutation and protein kinase C
exclusively by amplification.

kat, MT2, MT4, TL-OM1, and MT1 cells with an IRF4-specific
goat polyclonal antibody and control goat immunoglobulin
(Fig. 3B). We measured binding of IRF4 to the 3⬘-regulatory
region of the HELIOS gene. Levels of IRF4 bound to this gene in
PBMCs were 0.47% of input compared with 0.01% background
levels as measured by qPCR. Jurkat cells showed no significant
binding of IRF4. In contrast, IRF4 binding to the HELIOS gene
was 2.2-, 9.7-, 330-, and 15.5-fold greater than background levels in MT2, MT4, TL-OM1, and MT-1 cells, respectively. There
was a statistically significant difference of HELIOS DNA content between control and IRF4 immunoprecipitates from
PBMCs and MT4, TL-OM1, and MT1 cells.
CTLA4 is an immune checkpoint receptor and transcriptional target of IRF4 that is overexpressed in ATL (40). We
assayed for the presence of CTLA4 DNA in control IgG and
IRF4 immunoprecipitates (Fig. 3C). Activated PBMC control
immunoprecipitates and IRF4 immunoprecipitates yielded
0.03 and 0.42% of input DNA, respectively, as measured by
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Figure 1. IRF4 alterations in ATL. A, pie chart depicting types of genetic alterations of IRF4 in ATL. B, distribution of SNVs across the IRF4 protein sequence in
lymphoid malignancies, including ATL, obtained from the COSMIC database shows a predominance of SNVs in the DNA-binding domain. K59R and L70V, the
most common recurrent mutations in ATL, are located in the DNA-binding domain. C, the Lys-59 region of IRF4 is conserved across species. D, sequences of
other IRFs incorporate a lysine or arginine at the position corresponding to IRF4 Lys-59.

IRF4 activation in ATL

qPCR. Jurkat cells showed no significant binding of IRF4 to the
CTLA4 gene. In contrast, levels of IRF4 binding to the CTLA4
gene were 1.7-, 5.1-, 9.6-, and 7.8-fold above background in
MT2, MT4, TL-OM1, and MT1 cells, respectively. A statistically significant difference of CTLA4 DNA content between
control and IRF4 immunoprecipitates was detected in PBMCs,
MT4, and MT1 cells.
IRF4 has been shown to activate an interferon ␤ promoter–
driven luciferase construct (42). We therefore analyzed IRF4
chromatin immunoprecipitates for enrichment of interferon ␤
(IFN␤) promoter DNA (Fig. 3D). Activated PBMC IRF4-specific immunoprecipitates yielded no more IFN␤ genomic DNA
than control immunoglobulin immunoprecipitates. Levels of
IRF4 binding to the IFN␤ gene were 8.8-, 0.1, 2.7-, 15.3-, and
11.5-fold above background in Jurkat, MT2, MT4, TL-OM1,
and MT1 cells, respectively. These results were statistically significant in PBMCs, Jurkat cells, MT4 cells, TL-OM1 cells, and
MT1 cells.
cFLIP/cFLAR is a critical anti-apoptotic gene, which is a transcriptional target of IRF4 and overexpressed in ATL (43–47).
We therefore analyzed control and IRF4 chromatin immunoprecipitates for cFLIP/cFLAR DNA (Fig. 3E). Activated PBMC
control immunoprecipitates and IRF4-specific immunoprecipitates yielded 0.01 and 0.33% of input DNA. Levels of IRF4
binding to the cFLIP/cFLAR gene were 1.7-, 2.0-, ⬎1,000-, 15-,
and 2.6-fold above background in Jurkat, MT2, MT4, TL-OM1,
and MT1 cells, respectively.
As a control, we assayed for a control region 10 kilobases
upstream of the interferon ␤ start site in control and IRF4 chromatin immunoprecipitates by qPCR. There was no significant
difference in levels of this DNA region between control and
IRF4 chromatin immunoprecipitates of any of the assayed
T-cell lines.

IRF4 transcript is highly expressed in HTLV-transformed and
ATL cell lines
We measured IRF4 transcript in a control HTLV-1–negative
T-ALL cell line (Jurkat) and HTLV-1–positive cell lines MT2,
MT4, TL-OM1, and MT1 (Fig. 4A). As compared with Jurkat
cells, 37-, 121-, 10-, and 25-fold levels of expression of IRF4
transcript were observed in MT2, MT4, TL-OM1, and MT1
cells, respectively. These results were all statistically significant.
We sequenced the entire DNA-binding domain coding
sequence of IRF4 in MT2, MT4, TL-OM1, ED40515, and MT1
cells; we did not detect any mutations in the DNA-binding
domain coding sequence of any of these cell lines.
IRF4 transcriptional targets are highly expressed in
HTLV-1–transformed and ATL cell lines
Previous investigations to identify an IRF4 transcriptional
signature have identified a number of downstream targets (23).
To identify genes that are relevant to ATL, we examined downstream targets of IRF4, which were previously identified to be
highly expressed in ATL. BATF (43, 48), CTLA4 (40, 49), CCR4
(50, 51), c-FLIP (43–47), Helios (IKZF2) short isoform (40, 52),
interleukin-2 (IL-2) (53, 54), IL-9 (55–58), and IL-10 (59 –61)
have been shown to be transcriptionally regulated by IRF4 and
expressed in ATL. RNA levels of these genes in HTLV-1–
transformed and ATL cell lines were measured by qRT-PCR
and normalized to those of hypoxanthine guanine phosphoribosyl transferase (HGPRT) mRNA (Fig. 4). BATF transcript levels (Fig. 4B) were 41-, 124-, 3-, and 2-fold higher in MT2, MT4,
TL-OM1, and MT1 cells, compared with transcript levels in
Jurkat cells. CTLA4 transcript levels were 27-, 15-, 1-, and
2-fold higher in MT2, MT4, TL-OM1, and MT1 cells compared
with Jurkat cells (Fig. 4C). Chemokine receptor CCR4 transcript levels were 41-, 26-, 2.0-, and 19-fold higher in MT2,
J. Biol. Chem. (2018) 293(18) 6844 –6858
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Figure 3. IRF4 is overexpressed in ATL and bound to transcriptional target genes. A, Western blotting demonstrating IRF4 expression in CD3/CD28activated PBMCs and Jurkat, MT2, MT4, TL-OM1, MT1, and ED40515 cell lines. An immunoblot shows Tax protein expression. Env-Tax fusion protein in lane 3 of
the Tax blot (middle) is seen between 50 and 75 kDa and indicated by the top arrow. Tax-specific bands are seen in lanes 3 and 4 of the Tax blot at 40 kDa, as
indicated by the bottom arrow. Immunoblot for actin (bottom) shows actin expression as loading control. B–F, binding of IRF4 to HELIOS 3⬘-regulatory region
(B), CTLA4 gene (C), IFN␤ gene (D), cFLIP gene (E), and a control genomic region 10 kilobases upstream of the IRF4 start site (F) by IRF4, as demonstrated by a ChIP
assay in CD3/CD28-activated PBMCs and Jurkat, MT2, MT4, TL-OM1, and MT1 cells. B–F, results of four replicates. Error bars, S.E. *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍
0.001.

IRF4 activation in ATL

MT4, TL-OM1, and MT1 cells compared with Jurkat cells (Fig.
4D). The cFLIP transcript levels were 18-, 2.0-, 1.0-, and 4.0-fold
higher in MT2, MT4, TL-OM1, and MT1 cells compared with
Jurkat cells (Fig. 4E). IL-2 transcript levels were 2.3-, 1.6-, 0.9-,
and 2.4-fold greater in MT2, MT4, TL-OM1, and MT1 cells
compared with Jurkat cells (Fig. 4F). IL-9 transcripts were 462fold higher in MT2 cells than that in Jurkat cells, whereas no
significant differences were observed in MT4, TL-OM1, and
MT1 cells (1.0-, 0.9-, and 2.5-fold, respectively) (Fig. 4G). IL-10
transcript levels were 5.2-, 0.9-, 1.2-, and 2.3-fold higher in
MT2, MT4, TL-OM1, and MT1 cells compared with transcript
levels in Jurkat cells (Fig. 4H). IFN␤ transcript levels were 1.4-,
1.0-, 0.6-, and 1.5-fold higher in MT2, MT4, TL-OM1, and
MT1 cells compared with Jurkat cells (Fig. 4I).
Helios is a tumor suppressor that induces differentiation of
Treg cells (62, 63). We assayed for transcripts containing
HELIOS exon 7– coding sequence, which is usually present in
all HELIOS transcripts, including the abbreviated transcripts
previously detected in ATL. We detected 0.3-, 0.1-, 0.1-, and
1.1-fold higher transcript levels in MT2, MT4, TL-OM1, and
MT1 cells compared with Jurkat cells (Fig. 4J). Truncated
forms of Helios, lacking exon 2– or exon 3– coding
sequences, are expressed in ATL. These forms of Helios are
believed to act as dominant negative proteins of Ikaros
(IKZF1) (22, 64). Therefore, we also assayed for HELIOS
transcripts with intact exon 3 using primers complementary
to the junctions of exons 2 and 3 and exons 3 and 4, and we
observed that these transcripts were virtually undetectable
in MT2, MT4, TL-OM1, and MT1 cells, consistent with previous literature, whereas robust signals were detected in Jurkat cells (Fig. 4K). Given binding of IRF4 to the HELIOS 3⬘
enhancer noted in Fig. 2B, these data would suggest that
IRF4 may transcriptionally repress Helios.

6848 J. Biol. Chem. (2018) 293(18) 6844 –6858

Potential functional consequences of the K59R mutation
Whereas mutation of Lys-59 of IRF4 is unique to ATL, the
corresponding residue in other IRF family members is frequently altered in malignant cells. Mutations in IRF2 Arg-43
and IRF6 Arg-45 have been described in cervical and ovarian
cancers. Interestingly, IRF8 K45R is found in aggressive forms
of DLBCL (65). The mutation K59R is a conservative change
that replaces a positively charged lysine with arginine, which
possesses an isoelectric pH that is higher than that of lysine
(10.7 versus 9.7), and therefore it is likely to increase the net
positive charge in this region. We therefore hypothesized that
this amino acid change might preserve DNA binding while preventing ubiquitination, thus leading to increased protein levels
or enhanced DNA binding and increased transcriptional activity. It is interesting to note that a K123R mutation of IRF4
detected in 2% of patients with chronic lymphocytic leukemia
and multiple myeloma results in increased protein expression
of the mutant protein as compared with the WT protein (66,
67). Alternatively, given the concentration of positively charged
residues in this region of IRF4, K59R could lead to changes in
subcellular localization, although we were unable to identify a
canonical nuclear localization or nuclear export signal in this
region.
IRF4 is predominantly nuclear in HTLV-1–transformed cells
We examined the subcellular localization of IRF4 in control
CD3/CD28-activated PBMCs as well as HTLV-1–transformed
MT2, MT4, TL-OM1, and MT1 cells (Fig. 5, A and B). We
detected predominantly nuclear localization of IRF4 in MT2
cells (Fig. 5A, lane 3 versus lane 4), MT4 cells (Fig. 5A, lane 5
versus lane 6), TL-OM1 cells (Fig. 5B, lane 3 versus lane 4), and
MT1 cells (Fig. 5B, lane 5 versus lane 6). Histone H3 and HSP90
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Figure 4. Expression of IRF4 and IRF4-target genes in HTLV-1–transformed and ATL cell lines. A–K, RNA expression of IRF4 and its transcriptional targets
by qRT-PCR: IRF4 (A), BATF (B), CTLA4 (C), CCR4 (D), c-FLIP (E), IL-2 (F), IL-9 (G), IL-10 (H), IFN-␤ (I), HELIOS exon 7 (J), and exon 3 (K) in Jurkat, MT2, MT4, TL-OM1, and
MT1 cells. Error bars (representing S.E.) are indicated as well as p values for comparisons with Jurkat; *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001. The values represent
average of 3 replicates.

IRF4 activation in ATL

blots demonstrate purity of the nuclear and cytoplasmic fractions, respectively (middle and lower blots of Fig. 5, A and B).
K59R mutation enhances nuclear expression levels of IRF4
protein without affecting cytosolic levels
To assess the effects of the K59R mutation on subcellular
localization of IRF4, 293T cells were transfected with equal
amounts of either empty murine stem cell virus (MSCV)-IRESGFP vector or corresponding WT or K59R IRF4 expression
vectors. Forty-eight hours after transfection, subcellular fractionation was performed, and nuclear and cytosolic fractions
were separated by SDS-PAGE and then analyzed by immunoblot (Fig. 5C). Lanes 1, 2, and 3 show nuclear expression of IRF4
and histone H3 (nuclear loading control) and lack of nuclear
expression of HSP90, which is a cytosolic protein. IRF4 was
detected with an antibody to the C terminus of IRF4, a region
that is least conserved among different IRFs, which is distal to
the Lys-59 site and unlikely to affect antibody binding. Lane 1 of
the IRF4 blot indicates lack of expression of endogenous IRF4 in
293T cells. Comparing lane 3 with lane 2 of the IRF4 blot, there
is a 2.8-fold increase in nuclear levels of IRF4 K59R compared
with WT IRF4. The histone H3 immunoblot shows equal loading of nuclear protein in lanes 1, 2, and 3. The HSP90 immunoblot shows lack of expression of HSP90 in nuclear fractions.
Lanes 4 – 6 show expression of cytosolic IRF4 proteins, with
equal expression of WT and K59R mutant IRF4. The histone
H3 blot shows a lack of histone H3 in cytosolic fractions (lanes
4 – 6), confirming the purity of the subcellular fractions. The
HSP90 immunoblot shows equal loading of cytosolic protein in

lanes 4 – 6. Each of the transfected vectors expressed GFP from
an internal ribosomal entry site. The GFP immunoblot shows
equal expression of GFP in the cytosolic fractions (lanes 4 – 6).
This experiment was confirmed with three biological replicates
and with two different antibodies to distinct epitopes at the C
terminus of IRF4. Densitometry of IRF4 blots revealed a statistically significant 2.8-fold increase in nuclear levels of K59R
mutant IRF4 as compared with WT IRF4 (Fig. 5C, p ⫽ 0.03).
To assess whether similar findings are found in T-cell lines,
we transfected, by electroporation, Jurkat T cells with 50 g of
either MSCV-Empty vector, MSCV-IRF4 WT, or MSCV-IRF4
K59R mutant plasmid and analyzed the localization of IRF4 by
subcellular fractionation of cells at 24 h post-transfection (Fig.
5D). The IRF4 blot (first blot from the top) shows 6.2-fold
increased nuclear levels of IRF4 in K59R mutant–transfected
Jurkat cells as compared with WT IRF4 –transfected cells.
Cytoplasmic levels of IRF4 were not different. Note that there is
a nonspecific band in the empty vector–transfected lane of the
cytoplasmic fraction (lane 4, first blot from the top). Whole-cell
extracts showed 2.7-fold increased levels of K59R mutant IRF4
as compared with WT IRF4, which is accounted for entirely by
the increased nuclear levels of the K59R mutant. A histone H3
blot (second from the top) and HSP90 blot (third from the top)
indicate the purity of the subcellular fractions.
K59R mutant IRF4 possesses increased transcriptional activity
as compared with WT IRF4
To assess the transcriptional activity of the mutant compared
with WT IRF4, we used luciferase reporter plasmids. We coJ. Biol. Chem. (2018) 293(18) 6844 –6858
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Figure 5. Preferential nuclear localization of WT and K59R IRF4. A, Western blotting of nuclear and cytoplasmic fractions of IRF4 in CD3/CD28 activated
PBMCs and MT2 and MT4 cells showing predominantly nuclear localization of IRF4. B, Western blotting of nuclear and cytoplasmic fractions of IRF4 in
CD3/CD28-activated PBMCs and TL-OM1 and MT1 cells, demonstrating predominantly nuclear localization of IRF4. C, Western blotting depicting expression of
IRF4 in nuclear and cytoplasmic fractions of 293T cells transiently transfected with equal mass of MSCV-Empty-IRES-GFP, MSCV-IRF4 WT-IRES-GFP, and
MSCV-IRF4 K59R-IRES-GFP. Lanes 1–3 show nuclear fractions. Lanes 4 – 6 show cytosolic fractions. The IRF4 immunoblot shows increased nuclear levels of the
K59R mutant of IRF4 (top blot, lane 3) as compared with WT IRF4 (lane 2). Lanes 5 and 6 show equal IRF4 expression in the cytosolic fraction. The GFP blot shows
equal expression of IRF4 in the cytosolic fraction from the IRES sequence of the vectors, indicating equal transfection efficiency. The HSP90 blot shows equal
loading of cytosolic fractions, and lack of signal in the nuclear fractions confirms the purity of the subcellular fractions. The histone H3 blot shows equal loading
of nuclear fractions, and lack of signal in the cytosolic fraction further confirms the purity of the subcellular fractions. A bar graph depicts results from three
replicates of the experiment depicted in C. *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001. D, Western blotting depicting expression of IRF4 in nuclear and cytoplasmic
fractions of Jurkat T cells transiently transfected with equal mass of MSCV-Empty, MSCV-IRF4 WT, and MSCV-IRF4 K59R. Lanes 1–3, nuclear fractions; lanes 4 – 6,
cytosolic fractions; lanes 7–9, whole-cell lysates. The IRF4 immunoblot shows increased nuclear levels of the K59R mutant of IRF4 (top blot, lane 3) as compared
with WT IRF4 (lane 2). Lanes 5 and 6 show equal IRF4 expression in the cytosolic fraction. The HSP90 blot shows equal loading of cytosolic fractions, and lack of
signal in the nuclear fractions confirms the purity of the subcellular fractions. The histone H3 blot shows equal loading of the nuclear fractions, and lack of signal
in the cytosolic fraction further confirms the purity of the subcellular fractions.
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Figure 6. Effects of WT and K59R IRF4 on interferon ␤ promoter. A, luciferase expression from PGL2 vector with proximal promoter region of interferon ␤
expressed as a ratio to Renilla Luc expressed from the constitutive thymidine kinase promoter in 293T cells, co-transfected with empty vector or increasing
mass of MSCV-IRF4 WT-IRES-GFP plasmid or MSCV-IRF4 K59R-IRES-GFP plasmid; MSCV-IRF4 WT plasmid was transfected at a 3:1 ratio to MSCV-IRF4 K59R-IRESGFP plasmid to equalize nuclear expression levels while keeping total DNA constant. 3 g of total DNA was transfected (3 g of empty vector DNA in bar 1 and
the amount of empty vector decreased as IRF4 vector was increased to keep a total of 3 g. The luciferase graph represents results of five replicates. Error bars,
S.E. Significance was calculated using unpaired Student’s t test. B, Western blotting showing expression of IRF4 in nuclear lysates corresponding to samples for
the experiment shown in A.

Transcriptional activity of WT and K59R mutant IRF4 at AICEs,
EICEs, and ISREs
IRF4 heterodimerizes with BATF and JunD to activate transcription from AICEs (40) and with Ets family transcription
factors PU.1 and SpiB to activate transcription from EICEs (68).
IRF4 also homodimerizes to activate direct repeats of the IRF
binding sequence (GAAA), also known as an ISRE (34). We
tested the capacity of WT IRF4 and K59R mutant IRF4 to
induce transcription from these binding elements. For these
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experiments, we utilized S-tagged IRF4 constructs cloned into
the TriExNeo backbone because these plasmids expressed protein at significantly higher levels than the MSCV vectors. We
found consistent induction of the interferon ␤ Luc reporter
with S-tagged WT IRF4 (10-fold) and K59R IRF4 (23-fold),
demonstrating that the transcriptional potential of the
S-tagged constructs is similar to that of the untagged protein
(Fig. 7A). AICE-Luc, incorporating three repeats of the AICE
sequence, was co-transfected with TK-Renilla and either empty
S-tagged vector, S-tagged IRF4 WT, or S-tagged K59R mutant
IRF4 expression plasmids (Fig. 7B). We found 1.3-fold activation with WT IRF4 and 1.6-fold activation with K59R IRF4
mutant (four replicates). There was a statistically significant
difference between induction with K59R mutant and WT IRF4;
however, induction of the promoter by IRF4 was weak.
We next assayed induction of the AICE Luc construct with
WT and K59R mutant IRF4 in combination with BATF (Fig.
7C). We found 1.4- and 1.6-fold induction of AICE Luc with
WT and K59R mutant IRF4, respectively (four replicates). The
difference between empty vector and K59R IRF4 was statistically significant, although there was no statistically significant
difference between the induction of WT and K59R IRF4.
We then assayed the induction of EICE-Luc by WT IRF4 and
K59R IRF4. EICE-Luc incorporating three repeats of the EICE
sequence was co-transfected with TK-Renilla and either empty
vector or S-tagged IRF4 WT or S-tagged K59R mutant IRF4
expression plasmids (Fig. 7D). We observed 1.0- and 1.2-fold
induction of EICE-Luc with WT IRF4 and K59R IRF4, respectively (four replicates). The differences between K59R and
empty vector and K59R and WT IRF4 were statistically
significant.
We assayed induction of EICE Luc by WT IRF4 and K59R
mutant IRF4 in combination with the prototypical Ets family
transcription factor PU.1 (Fig. 7E). We observed 0.9- and 1.2fold induction with WT IRF4 and K59R IRF4, respectively (four
replicates). These values were not statistically significant.
We next assayed the induction of ISRE Luc by WT IRF4 and
K59R IRF4. ISRE-Luc incorporating three repeats of ISRE
sequence was co-transfected with TK-Renilla and either empty
vector or S-tagged IRF4 WT or S-tagged K59R mutant IRF4

Downloaded from http://www.jbc.org/ at Washington University on November 18, 2019

transfected 293T cells with interferon ␤ firefly luciferase (interferon ␤ Luc) plasmid and TK-Renilla (Renilla luciferase with
the thymidine kinase promoter) and either MSCV-IRES-GFP
empty vector or increasing quantities of vectors expressing WT
or K59R IRF4 (Fig. 6A). Empty vector and IRF4 WT plasmids
were transfected in a 3:1 ratio to K59R IRF4 plasmids to equalize nuclear levels based on our prior ⬃3:1 K59R/WT IRF4
nuclear expression ratios. The difference in mass of transfected
DNA was compensated by pcDNA3 plasmid, so that total
transfected DNA remained constant. We observed 3-, 4-, and
5-fold induction of luciferase with MSCV-IRES-IRF4 WT relative to empty vector with 0.75, 1.5, and 3 g of plasmid, respectively. With one-third the mass of K59R IRF4 expression plasmid (0.25, 0.5, and 1 g) we observed 3.7-, 8.4-, and 11.6-fold
induction of luciferase, respectively. The differences in results
between 1.5 g of WT IRF4 plasmid and 0.5 g of K59R mutant
IRF4 expression plasmid and between 3 g of WT IRF4 expression plasmid and 1 g of K59R expression plasmid were statistically significant (five replicates). We ensured that the nuclear
expression level of K59R did not exceed that of WT IRF4 by
separating nuclear extracts by SDS-PAGE and immunoblotting
for IRF4 (Fig. 6B). The IRF4 immunoblot shows the amount of
nuclear IRF4 protein increasing with increasing amounts of
transfected plasmid for WT IRF4 (lanes 2– 4) and for K59R
mutant (lanes 5–7). The largest difference in luciferase activation was between 3 g of transfected WT IRF4 plasmid and 1
g of K59R mutant plasmid (bar 4 versus bar 7; 5- versus 11.6fold induction); the corresponding lanes in the IRF4 immunoblot showed increased expression of IRF4 WT (lane 4) compared with K59R mutant IRF4 (lane 7), ruling out increased
nuclear levels as the cause of this difference.
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expression plasmids (Fig. 7F). We observed 2.4- and 2.9-fold
induction of ISRE Luc with co-transfection WT IRF4 and K59R
mutant IRF4, respectively (four replicates). There was a statistically significant difference in luciferase values between empty
vector and WT IRF4 and between empty vector and K59R
mutant IRF4, but not between WT IRF4 and K59R IRF4.
Given that we observed only weak induction of AICE Luc
and EICE Luc even with co-transcriptional activators of
these elements, and weak induction of ISRE Luc by IRF4, we
further examined the interferon ␤ promoter, which was
strongly induced by IRF4. Examination of this sequence
revealed mirror repeats of the IRF-binding element (TTTCCTTT/AAAGGAAA), which is distinct from previously
described AICEs, EICEs, and ISREs. We hypothesized that this
sequence might account for the strong induction of the interferon ␤ promoter by IRF4. We cloned three repeats of this
sequence upstream of the luciferase gene and tested this luciferase reporter construct for induction by IRF4 (Fig. 7H). We
observed 39- and 85-fold induction of luciferase with IRF4 WT
and K59R IRF4, respectively. The differences between WT IRF4
and empty vector, between K59R IRF4 and empty vector, and
between WT IRF4 and K59R IRF4 were statistically significant.
This would suggest that this mirror repeat sequence, which
allows for strong induction by IRF4, is a binding site for IRF4 in
the interferon ␤ promoter.
IRF4 knockdown increases apoptosis of an ATL cell line
Given the finding of recurrent mutations of IRF4 in ATL, the
increased nuclear localization of the mutant, and increased
transcriptional activity of the mutant, we further examined the
effects of IRF4 on the viability of an ATL cell line. HuT102 cells
were electroporated with control siRNA or an IRF4-targeted
pool of siRNAs; cells were lysed at 72 h, and lysates were sub-

jected to analysis by immunoblot (Fig. 8A). Cleaved caspase-3
was increased 7.5-fold in cells treated with IRF4-specific
siRNAs as compared with control siRNA-treated cells (bottom
blot, lane 2 versus lane 1). A blot for total caspase-3 shows a
corresponding decrease in total caspase in IRF4 siRNA-treated
cells as compared with control siRNA-treated cells (second blot
from bottom, lane 2 versus lane 1). IRF4 was knocked down by
81% in cells treated with IRF4 siRNA compared with control
siRNA-treated cells (top blot, lane 2 versus lane 1). Tax expression was not affected by IRF4 knockdown (second blot from
top). An actin blot shows equal loading of protein in both lanes
(third blot from top).
IRF4 increases abundance of murine T cells
In light of the finding of increased apoptosis in IRF4 knockdown cells in vitro, we further examined the effects of IRF4 on
T-cell abundance in vivo. C57/B6 WT mice were transplanted
with bone marrow-derived CD45.1⫹ Sca-1⫹ cells, which were
transduced MSCV-IRES-GFP empty retroviral vectors or IRF4
WT– or IRF4 K59R– expressing vectors (Fig. 8, B and C). Four
weeks after engraftment, peripheral blood was used for FACS
analysis of donor cells. GFP⫹ CD45.1⫹ cells (donor cells successfully transduced with the MSCV-IRES-GFP retroviral vectors) were classified as myeloid based on reactivity for Gr-1 and
Mac-1; B lymphocytes based on reactivity for B220; and T lymphocytes based on reactivity for CD4 or CD8. Fifteen replicates
were performed with control mice and 10 replicates each of WT
IRF4 – and K59R– expressing mice (Fig. 8, A and B). We
observed statistically and biologically significant increases in
GFP⫹ donor T cells, but not for B lymphocytes or myeloid cells
in mice that were transplanted with Sca-1⫹ bone marrow stem
cells transduced with WT IRF4 and K59R mutant IRF4. This
J. Biol. Chem. (2018) 293(18) 6844 –6858
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Figure 7. Effects of WT and K59R IRF4 on transcriptional reporter elements in 293T cells. A, -fold induction of firefly luciferase expressed from the
interferon ␤ proximal promoter by WT S-tagged IRF4 and S-tagged K59R mutant IRF4 over empty vector expressed as a ratio to Renilla luciferase expressed
from thymidine kinase promoter. B, induction of firefly luciferase expressed from an AP1-IRF composite element by S-tagged WT IRF4 and S-tagged K59R
mutant IRF4 expressed as a ratio to Renilla luciferase expressed from thymidine kinase promoter. C, induction of firefly luciferase expressed from an AP1-IRF
composite element by S-tagged WT IRF4 and S-tagged K59R mutant IRF4 transfected in combination with BATF expressed as a ratio to Renilla luciferase
expressed from thymidine kinase promoter. D, induction of firefly luciferase expressed from an Ets-IRF composite element by S-tagged WT IRF4 and S-tagged
K59R mutant IRF4 expressed as a ratio to Renilla luciferase expressed from thymidine kinase promoter. E, induction of firefly luciferase expressed from an Ets-IRF
composite element by S-tagged WT IRF4 and S-tagged K59R mutant IRF4 in combination with PU.1 expressed as a ratio to Renilla luciferase expressed from
thymidine kinase promoter. F, induction of firefly luciferase expressed from an ISRE element by WT IRF4 and K59R mutant IRF4 expressed as a ratio to Renilla
luciferase expressed from thymidine kinase promoter. G, sequence from the IFN-␤ Luc plasmid corresponding to nucleotides ⫺259 to ⫹43 relative to the
transcription start site was sequenced from the interferon ␤ Luc plasmid used in experiments depicted in Figs. 6A and 7A. A mirror repeat element in that
sequence is highlighted. H, induction of firefly luciferase expressed from a mirror repeat element by S-tagged WT IRF4 and S-tagged K59R mutant IRF4
expressed as a ratio to Renilla luciferase expressed from thymidine kinase promoter. A–G, results of four replicates; H, results of three replicates.
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demonstrates that IRF4 selectively increased T-lymphocyte
abundance in vivo.

Discussion
IRF4 is a key oncogenic transcription factor in common
lymphoid malignancies, such as ABC-DLBCL and multiple
myeloma, which are characterized by the activation of NF-B
(27, 28, 67, 68). HTLV-1-associated malignancies are initially
sustained by the potent viral oncogene Tax. Subsequently, Tax
expression is down-regulated to evade Tax-specific immunoediting, and somatically mutated host proteins take over as
drivers of proliferation and confer resistance to apoptosis and
therapy. ATL is characterized by mutations in the TCR, CD28,
and NF-B signaling pathways. IRF4 is transcriptionally upregulated by all of these pathways. Moreover, IRF4 is genetically
altered by amplification in 25% of ATL patients and point
mutation in 14% of patients (22). Mutations at K59R and L70V
are recurring mutations in ATL and represent the most common mutations of IRF4 identified in the COSMIC database of
cancer-associated mutations (22). Our exome sequencing data
revealed that 33% of acute ATL patients had a K59R mutation,
and 11% of patients had an L70V mutation. In one patient, the
K59R mutation emerged at progression from chronic ATL to
acute ATL, suggesting that this mutation arose with disease
progression. Therefore, there was a strong rationale for further
characterization of the role of IRF4 and the functional consequences of IRF4 mutations in lymphoid malignancies. We did
not detect mutations of the IRF4 DNA-binding domain in the
HTLV-1–transformed cell lines we studied. It is possible that
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selection of this mutation only occurs in vivo; however, the
small number of available cell lines precludes this conclusion.
We observed significantly increased IRF4 transcript and protein expression in HTLV-1–positive cell lines as compared with
HTLV-1–negative cell lines and activated PBMCs, consistent
with a role for IRF4 in their continued viability. We also
observed greater binding of IRF4 to regulatory genomic DNA of
its transcriptional targets in HTLV-1–positive cell lines and
CD3/CD28 activated PBMCs as compared with control Jurkat
cells.
We measured levels of transcriptional targets of IRF4,
including BATF, CTLA4, CCR4, cFLIP, IL-2, IL-9, and IL-10,
which were transcriptionally up-regulated, and also Helios
transcripts, which were down-regulated by IRF4. We did not
see a perfect correlation between IRF4 protein levels and
expression levels of its transcriptional targets in HTLV-transformed and ATL cell lines, suggesting that other transcription
factors may also be involved in their regulation.
We noted that the K59R mutation of IRF4 is in a highly conserved region of the DNA-binding domain. We hypothesized
that this might affect protein levels, subcellular localization, or
transcriptional activation potency. We noted that IRF4 is predominantly nuclear in HTLV-1–transformed and ATL cell
lines. We observed increased nuclear expression of K59R
mutant IRF4 as compared with WT protein, without changes in
cytosolic levels in transiently transfected 293T cells and Jurkat
T cells. This suggests that the difference in nuclear levels may
be due to differences in import or to sequestration by other
nuclear localized molecules.
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Figure 8. Effect of WT and K59R IRF4 on T-lymphocyte abundance in mice. A, Western blotting depicting expression of cleaved caspase-3 (as a measure of
apoptosis), total caspase-3, IRF4, Tax, and actin in lysates of HuT102 cells treated with control siRNA or a pool of siRNAs to IRF4. B and C, murine hematopoietic
stem cells (CD45.1, c-kit⫹, Sca-1⫹ bone marrow cells) were transduced with MSCV retroviral vectors, which express IRF4, IRF4 (K59R), or vector alone, as well as
GFP from an IRES and engrafted into irradiated CD45.2 recipients (n ⫽ 15, 10, and 10 for control, WT IRF4 – overexpressing, and K59R-overexpressing mice). Four
weeks after engraftment, peripheral blood was collected, and FACS was used to determine the abundance of CD45.1, GFP⫹ myeloid cells (Gr-1⫹, Mac-1⫹), B
cells (B220⫹), and T cells (CD4⫹, CD8⫹). Whereas no effect was observed on B cells or myeloid cells, the T-cell populations in IRF4-overexpressing mice were
significantly greater than controls, demonstrating that overexpression of IRF4 or IRF4 (K59R) results in T-cell proliferation in vivo. D, mechanisms for increased
oncogenic activity of the ATL-specific IRF4 K59R mutation.

IRF4 activation in ATL
response to tumor-associated antigens, as demonstrated in
multiple myeloma (76, 77).
In summary, IRF4 is highly expressed in ATL cell lines and
HTLV-1–transformed cell lines and stimulates the proliferation of T lymphocytes. Moreover, the K59R mutant form of
IRF4 is expressed at higher levels in the nucleus and possesses
increased transcriptional activity compared with WT IRF4,
strongly suggesting that this is an activating mutation in
ATL.

Experimental procedures
Cell culture
TL-OM1, MT1, and ED40515 Tax-negative ATL cell lines
were obtained from Edward Harhaj (Johns Hopkins University). The HuT102 ATL cell line was a gift from Patrick Green
(Ohio State University). Jurkat, 293T, MT2, and MT4 cells
were obtained from the National Institutes of Health AIDS
Repository.
Cell lines were maintained at 37 °C and 5% CO2 in complete
medium supplemented with 10% fetal bovine serum, 4 mM
L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin,
and 0.25 g/ml amphotericin B. PBMCs and T-cell lines,
including Jurkat, MT2, MT4, TL-OM1, MT1, and ED40515
cells, were maintained in complete RPMI medium. 293T cells
were maintained in complete Dulbecco’s modified Eagle’s
medium with 1 mM sodium pyruvate. For CD3/CD28 stimulation of PBMCs, preservative-free anti-CD3 (clone OKT3) and
anti-CD28 (clone ANC28) at 1 g/ml in PBS were bound to
tissue culture–treated polystyrene plates by incubation overnight. Plates were then blocked for 30 min with complete RPMI
medium before application of cells.
Transfections
293T cells were transiently transfected with Transit (Mirus
Bio) as per the manufacturer’s recommended protocol. Jurkat
cells were transfected with 50 g of MSCV-Empty vector,
MSCV-IRF4 WT, or MSCV-IRF4 K59R by electroporation at
340 V with 400-microfarad capacitance and parallel resistance of 124 ohms in a volume of 150 l of electroporation
buffer consisting of RPMI without antibiotics, bicarbonate,
or glutamine with 10 mM glycylglycine, pH 8.3, in a 4-mm
gap cuvette (Bulldog Bio). HuT102 was transfected with
either 75 pmol of control siRNAs or an siRNA pool targeting
the IRF4 3⬘-UTR by electroporation at 325 V with 400-microfarad capacitance and parallel resistance of 124 ohms in a
volume of 150 l.
Plasmids
Plasmids expressing WT IRF4 and K59R mutant IRF4 were
constructed by recombinational cloning of the respective
cDNAs using LR clonase into MSCV gateway vector. S-tagged
IRF4 and K59R mutant IRF4 constructs were made by amplifying the IRF4 coding sequences from the MSCV vectors
described above using the left primer CGCGGATCCGATGAACCTGGAGGGCGG and right primer CGCGAATTCTCATTCTTGAATAGAGGAA, which introduced BamHI and EcoRI
sites in termini of the amplified sequences that were ligated into
J. Biol. Chem. (2018) 293(18) 6844 –6858
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When we tested the capacity of K59R mutant IRF4 to activate
the interferon ␤ promoter, we observed that at equal nuclear
expression levels, the K59R mutant possessed more than twice
the transcriptional activation potency as compared with WT
IRF4. Surprisingly, when we tested the induction of more conventional IRF4-responsive promoter elements (i.e. AP1-IRF
and Ets-IRF composite elements and interferon-stimulated
response elements), we saw less increase over background.
Although these promoters were also activated more potently by
K59R mutant IRF4 than WT IRF4, the differences between signal and background were smaller.
Given the strong induction of the interferon ␤ promoter by
IRF4, we examined the promoter sequence for IRF-binding
sequences. We observed a mirror repeat of the IRF response
element in the proximal promoter. When we tested the effect of
IRF4 on this promoter element, we saw strong induction, which
would fully account for the high level of induction of the interferon ␤ promoter by IRF4. When we measured binding of IRF4
to the interferon ␤ promoter in HTLV-positive cell lines, CD3/
CD28-activated PBMCs, and Jurkat cells by a ChIP assay, we
observed binding in TL-OM1 cells and MT1 cells, both of
which are ATL-derived cell lines. Although interferon ␤ activates apoptosis of naive T cells, it allows for clonal expansion of
TCR-activated T cells in a cell-intrinsic manner and can inhibit
activation-induced cell death (69 –73). However, it is unclear
whether interferon ␤ plays a role in survival of ATL cells. It is
also possible that other genes with the same mirror repeat IRFbinding element may be the key targets of IRF4 required for
viability of ATL cells.
When we knocked down IRF4 expression in HuT102 ATL
cells in vitro, we found increased apoptosis, suggesting that
ATL cell lines depend on IRF4 expression for viability. When
we tested the capacity of hematopoietic cells transduced with
IRF4 to expand in vivo, we noted a selective effect of IRF4 on T
cells, further supporting a role for IRF4 in T-cell malignancies.
We did not see a statistically significant difference in T-cell
numbers between mice that received WT IRF4 –transduced
syngeneic bone marrow cells and those that received K59R
mutant IRF4 –transduced cells. It is unclear why a difference
was not identified, but it is possible that the increased activity of
K59R mutant IRF4 compared with WT IRF4 is only manifested
in human cells due to interactions with co-transcriptional
activators.
These data suggest that novel IRF4-targeted agents may have
efficacy in ATL and other IRF4-driven T-cell malignancies. The
immunomodulatory agent lenalidomide had activity in a phase
II trial in relapsed/refractory ATL (11). Lenalidomide has been
shown to depress IRF4 levels in multiple myeloma cell lines, and
sensitivity to lenalidomide correlates with IRF4 levels (74). We
did not see inhibition of ATL cell lines by lenalidomide in vitro
(data not shown), suggesting that, at least in ATL, responses to
lenalidomide may not be due to cell-intrinsic effects. IRF4 is
critical for the development of conventional type 2 dendritic
cells, which drive Th2, Th9, and Th17 responses, as opposed to
type 1 conventional dendritic cells, which drive Th1 responses
(75). It is possible that in ATL, lenalidomide may skew immune
responses toward a Th1-biased response, at the cost of a Th2
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siRNAs to IRF4
Sequences for IRF4 siRNA pool are CCACAGAUCUAUCCGCCAU, UGUCAGAGCUGCAAGCGUU, and GAAAAUGGUUGCCAGGUGA. siRNAs were purchased from Dharmacon/GE Life sciences.
Subcellular fractionation
Cells were washed twice with ice-cold PBS and resuspended
in hypotonic buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, and
3 mM MgCl2). One-twentieth volume of 10% Igepal CA630 was
added to each sample, and samples were vortexed vigorously
before spinning down nuclei at 8,000 rpm at 4 °C in a refrigerated microcentrifuge. Supernatants were used as cytosolic fractions. Nuclear pellets were lysed in Tris-HCl, pH 6.8, with 2%
Igepal CA630, 2% SDS, 10 mM sodium ␤-glycerophosphate, 10
mM sodium fluoride, 2.5 mM sodium pyrophosphate, 1 mM
sodium orthovanadate, and EDTA-free protease inhibitor mixture (Roche Applied Science) and sonicated on ice for 20 s
before use for analysis (modified from Ref. 78).
PAGE and Western blotting
Cells were lysed in Tris-HCl, pH 6.8, with 2% Igepal CA630,
2% SDS, 10 mM sodium ␤-glycerophosphate, 10 mM sodium
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fluoride, 2.5 mM sodium pyrophosphate, 1 mM sodium
orthovanadate, and EDTA-free protease inhibitor mixture
(Roche Applied Science/Sigma). Lysates were sonicated on ice
for 20 s. Protein concentration was determined using the bicinchoninic acid assay (79). Equal amounts of protein (40 g) were
loaded onto polyacrylamide gels, and electrophoresis was performed according to methods described by Ornstein (80) and
modified by Laemmli (81). Primary antibodies were diluted in
5% protease-free BSA, and secondary antibodies were diluted in
10% skim milk. Blots were imaged by enhanced chemiluminescence using a Chemidoc imager (Bio-Rad) and quantified using
the Bio-Rad proprietary software.
The following antibodies were used for Western blots. Rabbit
primary polyclonal antibody to HSP90 (SPA46) was obtained
from Stressgen Corp.; rabbit primary mAb to histone H3 clone
D1H2 was obtained from Cell Signaling Technology (catalog
no. 4499); D175 rabbit primary polyclonal antibody to cleaved
caspase-3 was obtained from Cell Signaling Technology (catalog no. 9661); mouse mAb to caspase-3 clone 3G2 was obtained
from Cell Signaling Technology (catalog no. 9668); goat polyclonal antibody to IRF4 (M17; sc6059) was obtained from Santa
Cruz Biotechnology, Inc.; goat polyclonal antibody to IRF4 was
obtained from Sigma-Aldrich (SAB2502031); rabbit polyclonal antibody to full-length Aequorea coerulescens GFP was
obtained from Clontech (catalog no. 632459); hybridoma 1316
for Tax1 was obtained from the NIH AIDS Repository.
ChIP
T-cell lines and CD3/CD28-activated (48 h) PBMCs were
washed once in ice-cold PBS and resuspended in 2% paraformaldehyde in PBS for 5 min for cross-linking at room temperature. The reaction was quenched by resuspension in 200 mM
glycine for 10 min. Cells were washed in PBS and then lysed in
Tris-HCl, pH 7.4, 150 milliequivalents/liter NaCl, 0.1% sodium
deoxycholate, 200 M putrescine, and 10% glycerol. The lysate
was sonicated in a bath sonicator with controlled temperature
⬍10 °C for 20 min. The lysates were cleared by a brief centrifugation at 15,000 rpm for 10 min in a refrigerated centrifuge.
Supernatants were used for ChIP analysis. DNA in each sample
was quantified using Hoechst 33342 fluorescence, and equal
mass of DNA from each sample was included in the immunoprecipitation reaction. Goat anti-IRF4 polyclonal antibody
(M-17 from Santa Cruz Biotechnology) and magnetic protein G
beads (Thermo Fisher Scientific) were added to the immunoprecipitation reaction overnight. After five washes with TrisHCl, pH 7.4, 150 milliequivalents/liter NaCl, and 200 M
putrescine, protein and DNA were eluted from the beads by
incubation at 65 °C overnight, which also served to reverse
DNA–DNA and DNA–protein cross-links. Samples were
simultaneously treated with RNase A overnight. Samples were
used for qPCR to quantify genomic areas of interest in the IRF4
immunoprecipitates. Immunoprecipitates with equal amounts
of DNA with IgG control were performed in parallel to determine the background signal by qPCR.
Genomic DNA was used as template for amplification in a
three-step amplification protocol using iTaq Universal SYBR
Green one-step kit on a Bio-Rad CFX Connect real-time system
with an extension temperature of 65 °C. Primers were designed
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the corresponding restriction sites in the Tri Ex Neo backbone
vector, so that WT IRF4 and K59R mutant IRF4 were expressed
with a hexahistidine tag and an S tag at the N terminus.
Interferon ␤ Luc plasmid incorporating two repeats of nucleotides ⫺259 to ⫹43 of the interferon ␤ proximal promoter was
a gift from the late Dr. Paula Marie Pitha-Rowe (Johns Hopkins
University). For the construction of AICE-Luc, EICE-Luc,
ISRE-Luc, and (TTTCCTTT)3 firefly luciferase reporter plasmids, pairs of partially complementary 5⬘-phosphorylated oligonucleotides incorporating three repeats of AICE, EICE,
ISRE, and TTTCCTTT mirror repeat sequences were annealed and ligated with 5⬘ NheI and 3⬘ HindIII sites in
PGL4.25Luc2CPminP plasmid, obtained from Promega Corp.
The sequences for the sense (S) and antisense (AS) oligonucleotides were as follows: AICE Luc (S), CTAGCGAAATGAGTCAGAAATGAGTCAGAAATGAGTCAA; AICE Luc (AS),
AGCTTTGACTCATTTCTGACTCATTTCTGACTCATTTCG; EICE Luc (S), CTAGCGGAAGTGAAAGGAAGTGAAAGGAAGTGAAAA; EICE Luc (AS), AGCTTTTTCACTTCCTTTCACTTCCTTTCACTTCCG; ISRE Luc (S), CTAGC
GAAAGGGAAAGTGAAAGGGAAAGTGAAAGGGAAAA;
ISRE Luc (AS), AGCTTTTTCCCTTTCACTTTCCCTTTCACTTTCCCTTTCG; (TTTCCTTT)3 Luc (S), CTGAGCTTTCCTTTTTTCCTTTTTTCCTTTA; (TTTCCTTT)3 Luc (AS),
AGCTTAAAGGAAAAAAGGAAAAAAGGAAAG. TK-R, in
which Renilla luciferase is driven by the thymidine kinase promoter, obtained from Promega, was used as transfection control for all luciferase experiments. BATF cDNA cloned into
pCMV SPORT6 backbone was obtained from the HarvardDFCC DNA Repository (HsCD00327682, originally provided
by the Mammalian Gene Corp.).
PU.1/Spi1 cDNA, cloned into pENTR223.1 backbone, was obtained from the Harvard-DFCC DNA Repository (HsCD00082621;
originally provided by the ORFeome Collaboration).

IRF4 activation in ATL

Genomic DNA sequencing
Genomic DNA from HTLV-1–transformed cell lines was
used as template to amplify sequence corresponding to exons 2
and 3 of the IRF4 gene. Forward and reverse primers used for
PCR were used for sequencing reactions to obtain forward and
reverse sequences. Sequences for forward and reverse primers
for amplification of exon 2 with the 3⬘ position from the IRF4
transcription start site indicated are as follows: IRF4 –1351 (forward), CCCCGCAGTGCAGAGCAGA; IRF4 –1677 (reverse),
GGGGACCCCGGGCTCTGTCT.
Sequences for forward and reverse primers for amplification
of exon 3 with 3⬘-position from the IRF4 transcription start site
indicated are as follows: IRF4 –3063 (forward), GACATGTATTTTGACTTTTCGTTCT; IRF4 –3293 (reverse), GCTGCCTCTGTTAGGTGA.
Whole-exome sequencing
Genomic DNA was extracted from PBMCs of nine ATL
patients and sonicated to generate 200 –300-base pair fragments. Exonic DNA fragments were captured with biotin-labeled probes covering the entire human exome. Pulldown was
performed with streptavidin beads, and eluted DNA was used
to make libraries with Illumina linkers and amplified using specific index primers for each patient’s DNA sample. For the
sequencing process, the ultra-high-throughput sequencing system, HiSeq 2500, was used, generating paired-end reads of 250
nucleotides each. Alignment and variant calling was performed
using Basespace.
qRT-PCR
RNA was extracted using TRIzol reagent. Total RNA was
used as template for reverse transcription and amplification of
cDNAs in a three-step amplification protocol using the iTaq
Universal SYBR Green one-step kit (Bio-Rad) on a Bio-Rad
CFX Connect real-time system with an extension temperature
of 65 °C. Exon-exon junction–spanning primers were designed

to reduce background from genomic DNA (except for interferon ␤, which has no introns). The following primers were
used for qRT-PCR: HGPRT1 (forward), GCCCTGGCGTCGTGATTAGT; HGPRT1 (reverse), GTTGACTGGTCATTACAATA; IRF4 (forward), TTGGCGTTCTCAGACTGCCG; IRF4
(reverse), AACGCTTGCAGCTCTGACAA; BATF-F (forward), CTCTCCTCCCCCTGGCAAACAGGACTC; BATF
(reverse), TCTGTTTCTCCAGGTCTTCGCTCTCCAGGT;
CTLA4 (forward), CATCCCTGTCTTCTGCAAAGCAATG;
CTLA4 (reverse), GTTGTAAGAGGGCTTCTTTTCTTTAGCATT; CCR4 (forward), CGGATATAGCAGACACCACCCTCGA; CCR4 (reverse), AACCCACTGGTCTGCTGCATAGTAG; cFLIP (forward), ATCCAGAAGTACAAGCAGTCTGTTCAA; cFLIP (reverse), GAAGGTGTCTCGAAGAAGCTCTGTC; IFN␤ (forward), GCAGCAGTTCCAGAAGGAGGAC;
IFN␤ (reverse), ACGAGTACTCAAAAGGGGACCA; Heliosexon7 (forward), TCTGATGCAGCACCCGCCAA; Heliosexon7 (reverse), GGCCTCTCTTTCCTGGGGTCG; Helios
exon2–3 (forward), GCCTCACCAAGTCACATGACAAGCACAAAT; Helios exon3– 4 (reverse), CAGTGGAAGGGGCGTTCACCAGTG; IL2 (forward), GGATTTACAGATGATTTTGAATGGAATTAATAATTA; IL2 (reverse), ATGAATGTTGTTTCAGATCCCTTTA; IL9 (forward), TTCCTCATCAACAAGATGCAGGAAGA; IL9 (reverse), ATGGCTGTTCACAGGAAAAATATGGAC; IL10 (forward), CTTCAGCAGAGTGAAGACTTTCTTTCAAAT; IL10 (reverse), TTCACAGGGAAGAAATCGATGACAGC.
Cycle number (Ct value) for each measured transcript was
converted to ratios of transcript abundance by taking the antilog to the base 2 of (⫺1 ⫻ Ct) value for each transcript and
dividing that by the antilog to the base 2 of (⫺1 ⫻ Ct) value for
hypoxanthine guanine phosphoribosyl transferase based on the
assumption of a 100% amplification efficiency.
Transduction of murine hematopoietic stem cells and
transplantation into recipient mice
Donor B6 CD45.1 mice were treated with 150 mg/kg 5-fluorouracil 6 days before marrow harvest. Harvested bone marrow
was enriched for Sca-1⫹ cells by autoMACS (Miltenyi). Cell
concentrations were adjusted to 5 ⫻ 105 cells/ml in medium
containing Stempro34 (Gibco) serum-free medium supplement, 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM
glutamine, 10 ng/ml stem cell factor (R&D Systems), 100 ng/ml
mouse thrombopoietin, and 4 g/ml Polybrene. Virus-like particles were generated in 293T cells by calcium phosphate–
mediated co-transfection of pCL-ECO packaging plasmid with
either the empty MSCV-IRES-GFP retroviral vector or vector
with coding sequence for WT IRF4 or K59R mutant IRF4
inserted by LR clonase recombinational cloning. Virus-like particles were harvested from the medium by ultracentrifugation.
Sca-1⫹ bone marrow cells were transduced with MSCV retroviral vectors by spin-infection at 250 ⫻ g at room temperature
for 2 h, followed by incubation for 1 h at 37 °C, and then transplanted by retro-orbital injection into lethally irradiated (9.5
grays) CD45.2 (C57/B6 WT) recipients (n ⫽ 15 for empty vector and 10 each for WT IRF4 and mutant IRF4). Four weeks
after engraftment, peripheral blood was collected, and FACS
was used to determine the abundance of CD45.1⫹, GFP⫹ myeJ. Biol. Chem. (2018) 293(18) 6844 –6858
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to flank IRF4-binding sites in the genomic neighborhood of
genes of interest, as determined using ENCODE data viewed
with the Integrated Genome Viewer (Broad Institute).
The following primers were used for qPCR: Helios-ChIP
(forward), AAATGAAAGAATTTGGCAAGAAAAA; HeliosChIP (reverse), CAAATATGAAAATTCAGGGTGAAAC;
CTLA4-ChIP (forward), GAGGCAATAAATGAAGAGGAAGGAC; CTLA4-ChIP (reverse), TACTCAAATTGAAACCCTGCTCAGAA; IFN␤-ChIP (forward), TGCTTTCCTTTGCTTTCTCCCAAGT; IFN␤-ChIP (reverse), CCCACTTTCACTTCTCCCTTTCAGT; cFLIP-ChIP (forward), ATGTCTTGTGTGGTAACATTTCAGC; cFLIP-ChIP (reverse), CAGAAAGTCAAAAGCATCAACAGGT; IFN␤ upstream-ChIP (forward),
GCTTTCAATGCCTATAAAATTTGC; IFN␤ upstream-ChIP
(reverse), AATCAACATAAAAAGTCTGGTTCTTG.
Input DNA was diluted 100-fold before qPCR. Cycle number
(Ct) for immunoprecipitated DNA was converted to percentage of input by dividing antilog to the base 2 of (⫺1 ⫻ Ct) for
immunoprecipitates by antilog to the base 2 of (⫺1 ⫻ Ct) for
input to give a percentage of input (accounting for the dilution
factor of 100 for input DNA).

IRF4 activation in ATL
loid cells (Gr-1⫹, Mac-1⫹), B cells (B220⫹), and T cells (CD4⫹,
CD8⫹). This was an unblinded experiment. Mouse strains used
for this study were obtained from the Jackson Laboratory (Bar
Harbor, ME).
Statistics
Data were analyzed by two-tailed unpaired Student’s t test
for samples of equal variance for statistical significance. Error
bars specify S.E.
All animal studies were performed as per animal protocols,
which were approved by the division of comparative medicine
at Washington University in Saint Louis. All human studies
were approved by the institutional review board of Washington
University in Saint Louis and abide by the principles of the
Declaration of Helsinki.
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